| ★ |  GDF2026 - FDA Commissioner Keynote | U.S. Food and Drug Administration @us_fda | 66 | Estados Unidos | |
| 12 |  GDF2026 - Closing Remarks | U.S. Food and Drug Administration @us_fda | 595 | Estados Unidos | 84 |
| 18 |  GDF2026 - Quality and Safety Assessment of Extractables/Leachables in Generic Drug Products | U.S. Food and Drug Administration @us_fda | 363 | Estados Unidos | 82 |
| 15 |  GDF2026 - Common Microbiology Deficiencies for Ophthalmic Suspension Drug Products | U.S. Food and Drug Administration @us_fda | 353 | Estados Unidos | 83 |
| 13 |  GDF2026 - Recent Trends in Pharmaceutical Freeze-Drying and Control Strategies | U.S. Food and Drug Administration @us_fda | 304 | Estados Unidos | 84 |
| 9 |  GDF2026 - Bioanalysis of Endogenous Drugs Using Surrogate Matrix Approach in ANDAs | U.S. Food and Drug Administration @us_fda | 279 | Estados Unidos | 85 |
| 2 |  GDF2026 - Overview of the FDA Product-Specific Guidance (PSG) Program | U.S. Food and Drug Administration @us_fda | 166 | Estados Unidos | 88 |
| 11 |  GDF2026 - Bioequivalence (BE) Recommendations for Bridging Pre- and Post-Mitigation Formulations | U.S. Food and Drug Administration @us_fda | 160 | Estados Unidos | 84 |
| 1 |  GDF2026 - Office of Generic Drugs (OGD) Keynote | U.S. Food and Drug Administration @us_fda | 144 | Estados Unidos | 90 |
| 7 |  GDF2026 - Best Practices for Safety Assessment of Nitrosamines in Generic Drugs | U.S. Food and Drug Administration @us_fda | 127 | Estados Unidos | 85 |
| 4 |  GDF2026 - Office of Pharmaceutical Quality (OPQ) Keynote | U.S. Food and Drug Administration @us_fda | 101 | Estados Unidos | 87 |
| 14 |  GDF2026 - Addressing Patent and Exclusivity Requirements – Regulatory Reminders | U.S. Food and Drug Administration @us_fda | 66 | Estados Unidos | 83 |
| 10 |  GDF2026 - Drug-Device Combination Products: A Quality Perspective | U.S. Food and Drug Administration @us_fda | 64 | Estados Unidos | 84 |
| 6 |  GDF2026 - Standardized Principles Used to Determine Maximum Daily Dose | U.S. Food and Drug Administration @us_fda | 57 | Estados Unidos | 85 |
| 8 |  GDF2026 - Prioritization Requests: Prioritizing Original and Supplemental ANDAs | U.S. Food and Drug Administration @us_fda | 49 | Estados Unidos | 85 |
| 16 |  GDF2026 - Common Bioequivalence (BE) Study Design Deficiencies and How to Avoid Them | U.S. Food and Drug Administration @us_fda | 47 | Estados Unidos | 83 |
| 17 |  GDF2026 - Using FDA’s Inactive Ingredient Database (IID): Best Practices and Considerations | U.S. Food and Drug Administration @us_fda | 47 | Estados Unidos | 83 |
| 20 |  GDF2026 - Factors that Can Facilitate Assessment of Type II Drug Master Files (DMFs) | U.S. Food and Drug Administration @us_fda | 43 | Estados Unidos | 82 |
| 3 |  GDF2026 - Suitability Petitions | U.S. Food and Drug Administration @us_fda | 41 | Estados Unidos | 87 |
| 5 |  GDF2026 - Orange Book: How Drug Product Listings are Added, Updated, and Maintained | U.S. Food and Drug Administration @us_fda | 39 | Estados Unidos | 86 |
| 19 |  GDF2026 - Proactive Strategies to Avoid Major Filing Deficiencies and Other Filing Stumbling Blocks | U.S. Food and Drug Administration @us_fda | 25 | Estados Unidos | 82 |